## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.5% below STRENGTH zone (4.0-10.0%); PEG 1.67 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($36.05)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 0, Bearish: 1)

**1. Why Centene (CNC) Shares Are Sliding Today**
- Source: Finviz | 20251216T212446 | Bearish | Relevance: 100%
- Centene (NYSE:CNC) shares fell 4.3% due to concerns that the House Speaker would block a vote to renew premium subsidies for the Affordable Care Act, significantly impacting the company as a key provider of government-backed health plans. This news, combined with existing pressures from rising medical expenses, casts uncertainty on Centene's future earnings and enrollment. Despite the drop, previous reports indicated positive sentiment from investment firms and funds, but the stock is down 35.6% year-to-date.

**2. Arizona court weighs Centene bid to force provider case to arbitration**
- Source: Beinsure | 20251215T180951 | Somewhat-Bearish | Relevance: 100%
- The Superior Court of Arizona is considering whether a discrimination lawsuit filed against Centene Corp. should be moved to arbitration. Centene's affiliate, Arizona Complete Health, argues that their contracts with healthcare providers mandate arbitration for dispute resolution. The underlying lawsuit alleges that state agencies and insurers, including Centene, discriminated against healthcare providers serving Native American populations by targeting them in fraud investigations that allegedly lacked proper investigation and caused reputational damage.

**3. Centene Corporation $CNC Shares Acquired by Thrivent Financial for Lutherans**
- Source: MarketBeat | 20251214T132353 | Neutral | Relevance: 100%
- Thrivent Financial for Lutherans has significantly increased its stake in Centene Corporation, acquiring an additional 635,153 shares, bringing its total ownership to 1,814,059 shares valued at $98.47 million. Several other institutional investors also adjusted their positions in Centene during recent quarters. The company's stock currently holds a "Hold" rating from analysts with an average target price of $38.44.

**4. National Bank of Canada FI Trims Stock Holdings in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251215T102419 | Neutral | Relevance: 62%
- National Bank of Canada FI reduced its stake in Elevance Health (NYSE:ELV) by 9.9% in Q2, selling nearly 20,000 shares but still holding 181,798 shares valued at approximately $70.7 million. Despite institutional investors owning 89.24% of the stock, analysts maintain a "Moderate Buy" rating with an average target price of $400.83. Elevance Health recently surpassed quarterly earnings estimates, reported strong revenue, and declared a $1.71 quarterly dividend.

**5. Hyperion Capital Advisors LP Purchases 9,000 Shares of Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251214T120809 | Somewhat-Bearish | Relevance: 61%
- Hyperion Capital Advisors LP increased its stake in Elevance Health (NYSE:ELV) by 34.3% in Q2, acquiring 9,000 additional shares to hold a total of 35,214 shares valued at $13.697 million. This makes Elevance Health the third-largest holding in Hyperion's portfolio, representing 8.6%. The company reported strong Q3 earnings, beating expectations with an EPS of $6.03 and revenue of $50.09 billion, and analysts have a "Moderate Buy" consensus rating with a target price of $400.83.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | Bernstein | $45 | $36 | +25% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | Bernstein | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Long-term trend broken: trading 10.9% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +1.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.67 elevated, pricing in significant growth expectations. Forward P/E 13.5x attractive for 43% earnings growth. Balance sheet: $1.1B free cash flow. Analyst sentiment positive (1 raises, avg +25%). Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.2B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.67 |
| Forward P/E | 13.5 |
| Current P/E | 19.3 |
| YoY Growth | 43.0% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 0.1% to 1.5% (+1.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.5pp (needs >4.0% for momentum thesis). MRS_5 (-1.4%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.89x), long-term trend not supportive. RSI neutral at 54. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.49% (CS: 56) | Neutral |
| RSI_14 | 54.1 | Neutral |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 1.014x | Above |
| vs SMA50 | 1.055x | Above |
| vs SMA200 | 0.891x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $38.97
- **Stop Loss:** $36.05 (7.5% risk)
- **Target:** $41.89 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 342
- **Position Value:** $13,327.74
- **Portfolio %:** 13.33%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*